Bivalirudin in 0.9% Sodium Chloride

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE- bivalirudin injection
Baxter Healthcare Corporation


Bivalirudin Injection is an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.


2.1 Recommended Dosage

The recommended dose of Bivalirudin Injection is an intravenous bolus dose of 0.75 mg/kg, followed immediately by a maintenance infusion of 1.75 mg/kg/h for the duration of the procedure. Five minutes after the bolus dose has been administered, an activated clotting time (ACT) should be performed and an additional bolus of 0.3 mg/kg should be given if needed.

Consider extending duration of infusion following PCI at 1.75 mg/kg/h for up to 4 hours post-procedure in patients with ST segment elevation MI (STEMI).

2.2 Dose Adjustment in Renal Impairment

Bolus Dose

No reduction in the bolus dose is needed for any degree of renal impairment.

Maintenance Infusion

In patients with creatinine clearance less than 30 mL/min (by Cockcroft Gault equation), reduce the infusion rate to 1 mg/kg/h. Monitor anticoagulant status in patients with renal impairment.

In patients on hemodialysis, reduce the infusion rate to 0.25 mg/kg/h [see Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].

2.3 Instructions for Administration

Thawing and Inspection of Plastic Container

Thaw frozen container at room temperature (25°C/ 77°F) or under refrigeration (5°C/41°F). Do not thaw by immersion in water baths or by microwave irradiation.
Do not add supplemental medication.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Check for minute leaks by squeezing container firmly. If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. Components of the solution may precipitate in the frozen state and will dissolve upon reaching room temperature with little or no agitation. Potency is not affected. Agitate after solution has reached room temperature. If after visual inspection the solution remains cloudy or if an insoluble precipitate is noted, if there are any leaks, or if any seals or outlet ports are not intact, the container should be discarded.
Do not refreeze thawed Bivalirudin Injection. Thawed solution is stable for 14 days under refrigeration (5°C/41°F) or 24 hours at room temperature (25°C/77°F). Discard any unused portion.

Drug Compatibilities

No incompatibilities have been observed with administration sets.

Do not administer the drugs listed in Table 1 in the same intravenous line with Bivalirudin Injection.

Table 1 Drugs Not for Administration in the Same Intravenous Line with Bivalirudin Injection


Amiodarone HCl

Amphotericin B

Chlorpromazine HCl



Prochlorperazine Edisylate



Vancomycin HCl


Injection, clear and colorless solution:

250 mg of bivalirudin per 50 mL (5 mg/mL) in a single-dose GALAXY container supplied as a frozen, premixed, iso-osmotic, sterile, nonpyrogenic solution. Ready to use. Each container contains 250 mg of bivalirudin equivalent to an average of 275 mg bivalirudin trifluoroacetate*.

*The range of bivalirudin trifluoroacetate is 270 to 280 mg based on a range of trifluoroacetic acid composition of 1.7 to 2.6 equivalents.

500 mg of bivalirudin per 100 mL (5 mg/mL) in a single-dose GALAXY container supplied as a frozen, premixed, iso-osmotic, sterile, nonpyrogenic solution. Ready to use. Each container contains 500 mg of bivalirudin equivalent to an average of 550 mg bivalirudin trifluoroacetate†.

The range of bivalirudin trifluoroacetate is 540 to 560 mg based on a range of trifluoroacetic acid composition of 1.7 to 2.6 equivalents.


Bivalirudin Injection is contraindicated in patients with:

Significant active bleeding
Hypersensitivity to Bivalirudin Injection or its components [see Adverse Reactions (6.2)].


5.1 Bleeding Events

Bivalirudin increases the risk of bleeding [see Adverse Reactions (6.1)]. Bivalirudin’s anticoagulant effect subsides approximately one hour after discontinuation [see Clinical Pharmacology (12.2)].

5.3 Thrombotic Risk with Coronary Artery Brachytherapy

An increased risk of thrombus formation, including fatal outcomes, has been associated with the use of bivalirudin in gamma brachytherapy [see Adverse Reactions (6.3)].


6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In the BAT trials, 79 of the 2161 (3.7%) of subjects undergoing PCI for treatment of unstable angina and randomized to bivalirudin experienced major bleeding events which consisted of: intracranial bleeding, retroperitoneal bleeding, and clinically overt bleeding with a decrease in hemoglobin >3 g/dL or leading to a transfusion of >2 units of blood.

6.2 Immunogenicity

As with all peptides, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to bivalirudin in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

In in vitro studies, bivalirudin exhibited no platelet aggregation response against sera from patients with a history of HIT/HITTS.

Among 494 subjects who received bivalirudin in clinical trials and were tested for antibodies, 2 subjects had treatment-emergent positive bivalirudin antibody tests. Neither subject demonstrated clinical evidence of allergic or anaphylactic reactions and repeat testing was not performed. Nine additional patients who had initial positive tests were negative on repeat testing.

Page 1 of 4 1 2 3 4

All resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2022. All Rights Reserved.